Allogene Therapeutics, Inc. (ALLO) Operating income 2018–2025
Allogene Therapeutics, Inc. (ALLO) annual operating income history from SEC filings — each fiscal year as reported.
-$209.3MFY2025 · since FY2018: -$192.8M → -$209.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$209.3M | +23.4% |
| FY2024 | -$273.2M | +16.6% |
| FY2023 | -$327.7M | +2.3% |
| FY2022 | -$335.5M | -86.2% |
| FY2021 | -$180.2M | +30.2% |
| FY2020 | -$258.2M | -27.8% |
| FY2019 | -$202.0M | -4.8% |
| FY2018 | -$192.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ALLO financial trends
ALLO RevenueALLO Net incomeALLO Net marginALLO Gross profitALLO Gross marginALLO Operating marginALLO Operating cash flowALLO Free cash flowALLO Capital expendituresALLO Return on equityALLO Stock buybacksALLO Dividends paidALLO Total assetsALLO Total liabilitiesALLO Shareholders’ equityALLO overview →